Tag Archives: Skyrizi

AbbVie pegs growth to booming Skyrizi, Rinvoq in post-merger future. But neurology could be a ‘sleeper’

With its $ 63 billion merger with Allergan in the rearview, the new AbbVie is facing a major challenge as U.S. biosimilars for Humira cast a pall over the near-term future. But AbbVie figures its homegrown prospects will keep driving growth—and a couple of surprises from Allergan could make the forecast even rosier.  After six… Read More »

FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis Print this page NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ — AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic… Read More »